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ABSTRACT
Objectives: To examine policymakers and providers’
views on pre-exposure prophylaxis (PrEP) and their
willingness to support its introduction, to inform policy
and practice in this emerging field.
Design: Semistructured qualitative interview study.
Setting: Peru, Ukraine, India, Kenya, Uganda,
Botswana and South Africa.
Participants: 35 policymakers, 35 healthcare workers
and 21 non-governmental organisation representatives
involved in HIV prevention.
Results: Six themes emerged from the data: (1)
perceived HIV prevention landscape: prevention
initiatives needed to be improved and expanded; (2)
PrEP awareness: 50 of 91 participants had heard of
PrEP; (3) benefits of PrEP: one component of the
combination prevention arsenal that could help prioritise
HIV prevention, empower key populations and result in
economic gains; (4) challenges of PrEP: regimen
complexity, cost and cost-effectiveness, risk
compensation, efficacy and effectiveness, stigmatisation
and criminalisation, information and training and
healthcare system capacity; (5) programmatic
considerations: user eligibility, communication strategy,
cost, distribution, medication and HIV testing
compliance and (6) early versus late implementation:
participants were divided as to whether they would
support an early introduction of PrEP in their country or
would prefer to wait until it has been successfully
implemented in other countries, with around half of
those we spoke to supporting each option. Very few
said they would not support PrEP at all.
Conclusions: Despite the multiple challenges
identified, there was general willingness to support the
introduction of PrEP. Yet, strengthening existing HIV
prevention efforts was also deemed necessary. Our
results suggest that an effective PrEP programme
would be delivered in healthcare facilities and involve
non-governmental organisations and the community
and consider the needs of mobile populations.
Comprehensive information packages and training for
users and providers would be critical. The cost of PrEP
would be affordable and possibly segmented.
Extensive counselling and innovative monitoring
measures ought to be considered.
INTRODUCTION
HIV incidence is stabilising and beginning to
decline in many countries with generalised
epidemics. Further efforts should now focus
on consolidating this trend.1 New prevention
approaches are being considered that might,
in combination with existing ones, help
achieve this goal. Following both successful
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ARTICLE SUMMARY
Article focus
- Understanding the attitudes, perceptions and
preferences of key stakeholders towards PrEP
to identify important programmatic aspects that
may enhance or hinder its effectiveness.
Key messages
- Policymakers, healthcare workers and NGOs,
particularly from Sub-Saharan Africa, would be
willing to support PrEP if proven cost-effective.
- PrEP was envisaged as part of a combination
prevention strategy deeply rooted in and driven
by its beneficiaries.
- To effectively tackle the HIV epidemic, reducing
stigmatisation against those at higher risk of
infection and strengthening existing prevention
programmes is as critical as introducing new
ones.
Strengths and limitations of this study
- This is the first international study on key
stakeholders’ preferences and concerns
regarding PrEP and how best to address these
at a policy and service level.
- The interview guides and local interviewers’
training were standardised, which facilitated
data comparability.
- Relevant PrEP stakeholders were recruited.
- Limitations include the largely hypothetical
nature of the addressed PrEP characteristics,
potential social desirability bias and purposive
recruitmentdmainly in urban areas.
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and futile results in recent clinical trials,2e8 the use of
antiretrovirals to prevent HIV transmission (treatment
for prevention) or acquisition (pre-exposure prophylaxis
(PrEP)) has become a focus of HIV/AIDS policy
discussions. Although further clinical evidence will be
needed to determine optimal regimens and delivery
mechanisms,9 multi-disciplinary preparatory work needs
to be undertaken to identify where existing and poten-
tial modalities may fit best within an integrated HIV
prevention package.
Previous work on the implications of a future PrEP
implementation has highlighted the importance of
engaging relevant stakeholders in a consultation process
designed to strengthen, legitimise and ultimately
enhance its sustainability and effectiveness.10e12 Under-
standing the preferences and concerns of policymakers
and providers towards PrEP, drawing on their experience
in designing and delivering comparable programmes, is
therefore paramount to the success of this prevention
approach.13e15
This article reports on qualitative research exploring
policymakers, healthcare workers and non-governmental
organisations’ (NGOs) perspectives on oral and paren-
teral PrEP in seven countries: Peru, Ukraine, India,
Kenya, Uganda, Botswana and South Africa. The
research presented here complements a study on atti-
tudes and acceptance of PrEP among potential users
reported elsewhere.16 The research presented here aims
to inform priority setting, programme design, and
implementation, should PrEP prove cost-effective, and
complements a study on attitudes and acceptance of
PrEP among potential users reported elsewhere.
METHODS
A qualitative approach is most appropriate in an
exploratory in-depth study of this sort.17 Face-to-face
individual interviews were therefore conducted between
November 2010 and March 2011 with policymakers,
healthcare workers and NGO representatives responsible
for or involved in HIV prevention in major cities of seven
countries with diverse HIV epidemics: Peru, Ukraine,
India, Kenya, Uganda, Botswana and South Africa.
Participants were purposively selected using a combina-
tion of criterion and snowball sampling.
Ipsos MORI, an international social and market
research company, coordinated the data collection.
Interviews were conducted by experienced local senior
researchers. Interviewers were trained face-to-face by
both our team and/or Ipsos MORI. They were also
provided with a comprehensive interview manual, which
contained background on PrEP research, frequently
asked questions, information on participant eligibility,
detailed interview instructions and a consent form in
countries where local ethical approval required written
consent. All participants provided verbal consent. Inter-
views took place in a private office at the participants’
work place and lasted between 45 and 60 min. Interview
guides and materials were translated into Spanish (Peru)
and Russian (Ukraine) by the local research team and
checked in London by professional translators for
consistency and quality. In India and Sub-Saharan
African countries, interviews were conducted in English.
We used a semistructured and probing interview guide
constructed through expert consultations and a litera-
ture review. Before commencing, participants were
informed that their answers would be anonymised and
treated with strict confidentiality. Participants were first
asked about their role, involvement with HIV preven-
tion, perceptions of their countries’ HIV prevention
efforts and awareness of PrEP. To provide all participants
with a minimum level of background knowledge, inter-
viewers subsequently read a description of hypothetical
and real PrEP attributes, including its ineffectiveness
against other sexually transmitted diseases; its route of
delivery as a daily and before-and-after-sex pill and
eventually as a monthly and bimonthly injection; its mild
temporary side effects including tiredness, headaches
and gassiness; its partial protective efficacy against HIV,
especially if not taken as directed, and the need for
frequent HIV testing. It was stressed that PrEP was
undergoing clinical trials and its characteristics
remained uncertain. Participants were then asked to
rank their concerns in order of importance. They were
also asked to identify the benefits of PrEP, if any.
Subsequently, they were asked to describe what an
effective PrEP programme would look like in their
countries. Participants were finally asked whether they
would support PrEP being introduced at an early stage,
a later stage or not at all.
All interviews were digitally recorded, transcribed and
translated into English by professional translators where
necessary and were analysed independently by AW, GBG
and ABE to ascertain inter-rater coding reliability.18
Using thematic analysis,19 20 an initial categorising
system was developed based on the study objectives and
the interview guides. We identified new themes and sub-
themes emerging from the data analysis, which were
included when consensus was reached regarding their
relevance. A final thematic index was produced to code
all data.
RESULTS
We conducted a total of 91 interviews (13 per country)
including 35 policymakers, 35 healthcare workers and 21
NGO representatives. Fifty-one participants were men
and 42 were women. Participants’ eligibility criteria are
described in table 1. We present our findings across
countries and job roles, highlighting areas of conver-
gence and divergence around six themes: perceived HIV
prevention landscape, PrEP awareness, perceived bene-
fits of PrEP, perceived challenges of PrEP, programmatic
considerations and early versus late implementation.
Perceived HIV prevention landscape
Peruvian participants mentioned that their HIV
epidemic had reached a plateau with a significant
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reduction in mortality. Men who have sex with men
(MSM), especially transsexuals, were identified as the
most affected group. Stigma, low self-esteem and
substance abuse were frequently referred to as under-
lying determinants of high HIV incidence among MSM.
Cultural and religious barriers, insufficient resources
and the recent decentralisation of Peru’s healthcare
system, which had led to inefficiencies in the provision of
services, were raised as the main reasons behind the
current HIV prevention deficiencies. A mismatch
between treatment and prevention expenditure and the
comparatively low HIV incidence among the beneficia-
ries of prevention programmes were mentioned as main
causes for concern.
Most Ukrainian participants agreed that HIV
prevention had recently become a priority on their
government’s agenda. Nonetheless, they raised
concerns regarding the accuracy of the official HIV
incidence data and the pervasive criminalisation and
stigmatisation of key populations (injecting drug users
(IDUs), female sex workers and MSM), which in turn
hindered their access to prevention programmes.
Participants felt that reducing Ukraine’s dependency
on international donors, increasing and optimising
public resources for HIV prevention, as well as
involving communities in the design of prevention
programmes, strengthening advocacy work and raising
awareness was urgently needed to increase the impact
and sustainability of prevention efforts.
Similarly, Indian participants felt that their country’s
HIV prevention efforts were insufficient and identified
sex workers, MSM, truck drivers, serodiscordant couples
and IDUs as populations at higher risk of infection.
Key HIV prevention challenges included lack of access
to condoms and difficulty negotiating condom use,
stigmatisationdoften from healthcare workersdand
unknown HIV status. Like in Peru, most noted that
investment in prevention programmes was often
inversely proportional to the risk of the populations they
targeted and some suggested that the available HIV
incidence and prevalence figures were underreported.
The perceptions of participants from Sub-Saharan
Africa were comparable. Most agreed that HIV incidence
was highest among young people, especially women, and
stable couples. However, MSM (including prisoners),
female sex workers, fishermen and truck drivers were
also mentioned among those at higher risk of infection.
Participants acknowledged their countries’ efforts to
reduce HIV incidence, yet they felt these remained
suboptimal. Key prevention challenges included lack of
resources and competing priorities, specifically HIV
treatment; stigma and criminalisation of groups at
higher risk, which frequently impeded their access to
HIV services; inadequate communication strategies,
often mono-lingual (English) and focused on certain
groups; over-reliance on the ABC approach (abstinence,
being faithful and using condoms); prevalence of
multiple concurrent partnerships; women’s vulnerability
Table 1 Participant eligibility criteria
Job role Eligibility criteria
Policymakers (5 per country)
National policymakers (3) < Senior officials
< Portfolio includes HIV prevention
Local policymakers (2)* < Working in local authorities outside the capital city
< One local authority is at the forefront of
HIV prevention
< Portfolio includes HIV prevention
Frontline healthcare workers (5 per country)y
Community health worker (1) < Involved in HIV prevention
Healthcare professionals working in a reproductive health clinic (1) < Doctor or registered nurse
< Involved in HIV prevention
Healthcare professionals working in an HIV clinic (2) < At least one doctor
< Involved in HIV prevention
HIV/AIDS Voluntary Counselling and Testing (VCT) counsellor < Lay counsellor, trained counsellor or
registered nurse who is a counsellor
NGOs (3 per country)
Staff of supranational NGO (1) < Senior staff
< Involved in HIV prevention
Staff of NGOs who work with vulnerable populations (2) < Senior staff
< National or regional influence
< One is supportive of HIV prevention
*In Peru, we only interviewed national policymakers due to the centralised nature of its HIV policy-making process.
yWorking in public, non-profit or private healthcare facilities.
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and inability to negotiate the use of condoms and
donors’ silo approach and often divergent agendas.
PrEP awareness
Participants’ degree of awareness about PrEP varied
across countries and job role, as reported in table 2. Fifty
of ninety-one participants were aware of PrEP before the
interview took place.
Perceived benefits of PrEP
There was general consensus across countries and job roles
regarding the benefits of PrEP, as reported in table 3 and
illustrated in box 1. Most participants emphasised that
PrEP was an additional prevention tool for those most at
risk of infection, which would complement and possibly
enhance existing methods. They also felt that imple-
menting PrEP as part of a combination prevention strategy
could result in amuch needed increase in public resources
devoted to HIV prevention. PrEP was widely perceived as
an empowering mechanism that could enhance users’
well-being, reduce the burden of the disease and have
a positive impact on countries’ economies.
Perceived challenges of PrEP
The identified challenges of PrEP were largely compa-
rable. Yet, there were differences in frequency and
ranking order, particularly across countries, as reported
in table 4 and illustrated in box 2.
Most participants pointed out that the PrEP regimen
would be difficult to follow. Identified barriers to uptake
included the following: side effects, particularly in
Ukraine and Peru; adherence, predominantly in South
Africa; and the emergence of resistance, mainly in
Botswana, Kenya and Uganda. With the exception of
India, the cost and cost-effectiveness of PrEP were also
frequently mentioned as key concerns. An increase in
risk behaviours (ie, decrease in condom use, increase in
sexual activity and number of different partners) was
a relevant issue among Indian, South African and
Batswana participants. With the exception of Kenya and
Uganda, a high PrEP efficacy and/or effectiveness was
generally deemed critical for making the case for allo-
cating public funds to this initiative. In India, it was
frequently stressed that effectiveness data should be
generated by local clinical trials. Some participants felt
that reaching key populations would pose significant
challenges due to the stigmatisation and criminalisation
of certain sexual practices, which could in turn have an
impact on governments’ willingness to introduce PrEP.
This held particularly true in Peru and to a lesser extent
in Ukraine, India and Uganda. The provision of
adequate information and training to healthcare
providers and users was also deemed challenging,
particularly in Ukraine, Uganda and South Africa. Some
participants mentioned that their health systems were
overloaded and raised concerns regarding their capacity
to offer PrEP. Participants from Southern Africa felt that
their healthcare workforce was already overstretched,
whereas Indian participants’ concerns revolved around
logistics and continuity of supply.
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Programmatic considerations
There were many commonalities in participants’ views
and recommendations on what an eventual PrEP
programme should look like. An overview of key sub-
themes is provided below.
User eligibility
Participants from countries with concentrated epidemics
(Peru, Ukraine and India) felt that prioritising key
populations would be a cost-effective approach. Yet,
concerns were raised regarding the ability of IDUs and
mobile populations to comply with a PrEP regimen. A
confidential and tactful approach was perceived as critical
to prevent further stigmatisation and avoid jeopardising
demand among those at higher risk of HIV infection.
Offering PrEP to sex workers’ clients was also suggested.
Most participants from countries with generalised
epidemics (Sub-Saharan Africa) would offer PrEP to
young people and serodiscordant couples first. Other
priority populations included sex workers, MSM, truck
drivers and fishermen. However, most felt that due to the
characteristics of their epidemics, prioritisation would be
challenging.
Communication strategy
An effective communication strategy would involve Minis-
tries of Health, relevant HIV services and civil society. Peer
educators, community leaders and social networks were
regarded as crucial components of a PrEP communication
campaign, albeit complemented with targeted mass media
advertising, as they would provide access to and colloquial
information exchange with key populations.
Participants noted that training PrEP providers and
those involved in a communication campaign was crit-
ical. For example, a Ukrainian nurse working at an HIV
clinic pointed out “We should teach our staff how to
Table 3 PrEP benefits*
Policymakers Healthcare workers NGOs
Peru < Prevention tool for most
at risk
< Additional prevention
strategy
< Additional prevention strategy
< Tool for high-risk groups
< Potential economic gains
< Opportunity to make prevention
a priority
< Empowering prevention tool
< Additional prevention strategy
< Opportunity to increase
investment in prevention
Ukraine < Additional prevention
strategy
< Increased well-being
< Empowerment of most
at risk
< Alternative prevention strategy
< Potential economic gains
< Reduce HIV incidence
< Additional prevention strategy
India < Alternative prevention
strategy for serodiscordant
couples
< Not gender specific
< Additional prevention tool
< Potential economic gains
< For serodiscordant couples
< Additional prevention strategy
Kenya < Alternative prevention
strategy
< Potential economic gains
< May benefit most at risk
< Empowering most at risk
< Alternative prevention strategy
< Potential economic gains
< May benefit most at risk
< Additional prevention strategy
< May benefit most at risk
Uganda < Reduce HIV incidence
< Potential economic gains
< May benefit most at risk
< For those who cannot
negotiate condom use
< Alternative prevention strategy
< For those who cannot negotiate
condom use
< Potential economic gains
< Reduce HIV incidence
< May benefit most at risk
Botswana < Reduce HIV incidence
< Reduce cost of treatment
and care
< HIV-free newborns
< Protect HWs
< May benefit most at risk
< Reduce HIV incidence
< Help avoid family breakups
< HIV-free newborns
< Potential economic gains
< Alternative prevention strategy
< For those who cannot negotiate
condom use
< For high-risk periods
South Africa < Reduce HIV incidence
< May help achieve Millennium
Goalsy
< For those who cannot
negotiate condom use
< Alternative prevention strategy
< For those who cannot negotiate
condom use
< May help prevent other illnessesz
< May help to fight stigma
< Alternative and empowering
prevention strategy for most
at risk
*In descending order from most recurrent.
yHIV related, maternal and child health and gender equality.
zAssociated with AIDS (ie, cervical cancer and tuberculosis).
HW, healthcare worker; NGO, non-governmental organisation; PrEP, pre-exposure prophylaxis.
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approach people, how to present PrEP to them to
prevent them from saying it’s non-sense and they don’t
believe in it” (Uk08).
A PrEP communication campaign was also perceived
as a potential vehicle of messages against stigma and
prejudice, contributing to address these fundamental
barriers. Some suggested that a consultation process
would be essential to meet communities’ needs and
tackle any concerns from the outset.
Cost
Most participants agreed that PrEP should be free or
heavily subsidised. Some, however, felt that a cost-
segmented strategy was a more sustainable approach. It
was noted that asking users to pay an affordable amount
for the medication and associated services could improve
adherence, as illustrated by a Ukrainian national policy-
maker: “. people should pay at least for some percentage
of the medicine cost . If they pay this money they will
naturally keep in mind the necessity to take this pill .
because they have bought it at their own expense. They
had to work to buy PrEP . I mean, the attitude is
completely different in this case. It’s not a freebie” (Uk02).
Distribution
There was widely held support for PrEP to be managed
by the Ministries of Health and distributed through
existing public and NGO-based healthcare services. It
was stressed that PrEP distribution channels had to
comply with strict privacy and confidentiality codes of
practice. For example, an Indian local policymaker
stressed: “If everyone takes PrEP, then there will be no
stigma. But if you will start with certain groups (there will
be) . so confidentiality has to be taken care of when
you are giving such medicines” (I04).
Distributing PrEP in antiretroviral therapy (ART)
centres was not favoured, as users may worry about being
associated with HIV patients. Some participants felt that
distributing PrEP through pharmacies would reduce
transportation costs and facilitate uptake. Yet, most
agreed that other essential PrEP services (ie, counselling,
HIV testing) had to be delivered at a healthcare setting.
Providing PrEP to highly mobile populations such as sex
workers and truck drivers was raised as an important
hurdle. This was illustrated by a Kenyan doctor working
at an HIV clinic: “ . we will have to force them to start
going to a facility regularly, not just for the test but for
the drug, for the test they can go anywhere but to get
a drug . you have to register somewhere and go there
regularly . I think that may discourage them because
some of them are highly mobile groups” (K08).
Medication and HIV testing compliance
People’s willingness and ability to take long-term
prophylactic medication and to frequently get tested for
HIV was raised as a major challenge. Those who raised
this considered offering tailored information and
Box 1 Pre-exposure prophylaxis (PrEP) benefits: important topics
Combination prevention
“Consider you are a truck driver. at high risk and eligible for PrEP, so we test you, you are negative, you are not circumcised,
so we circumcise you. Then as you leave, we give you PrEP and we give you a month supply of condoms.. We would have
examined to see if you have any STDs.. You’ll be asked to come back after one month for a supply of PrEP and condoms..
The entry point for this truck driver was PrEP. He was eligible for PrEP but we tested him and testing is a very critical tool, we
circumcised him, we screened him for STDs, we gave him condoms. this person has accessed more than PrEP. We hope that
this will happen as well.” (K03, national policymaker).
“Taking into account the fact that there are no effective vaccines or effective prophylaxis, all prophylactic measures which could
be used simultaneously or consecutively, raise the safety of potential victims of the virus” (Uk11, supranational NGO).
Prioritising HIV prevention
“We need to treat [HIV positives], reduce their viral load, improve their CD4 count and then that way we reduce the trans-
missibility levels. Also, it is good for us to protect the ones who are HIV negative. we need to weigh the two and see how we
can balance [them] so that we don’t lean on one side” (K05, local policymaker).
“. I do hope that with a plan, with all these discussions we really come back with a determination to revolutionise prevention
and I think this tool would be one of the things that will help us” (SA10, VCT counsellor).
Empowering key populations
“We have had a snag around the ABC strategy because it does not work for women. Because their rights are abused, even if she
abstains, someone will rape her. There are social factors that glorify male infidelity, however faithful you are as a woman, your
husband is having sex with other women and that is ok in Ugandan society. Condom use can only work if you negotiate for sex. In
our context it’s mostly men who have the power to decide how and when to have sex with women” (Ug12, NGO representative).
“ . if you are a female sex worker or a transgender, you may have a partner who is not willing to use a condom .. In such
scenarios, where condom negotiation is low, then PrEP works” (I11, NGO representative).
Financial gains
“ . [HIV negative] people do not stop working and that means . economic gain on a domestic and national level” (P09,
doctordHIV clinic).
“. the maternal death rate will drop. Neonatal death rate will drop. The rate of (hospital) admissions will drop. There will be no
orphans. And . we won’t have to pay more money for grants for those kids” (SA01, national policymaker).
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counselling, devising a contractual agreement between
the provider and the user, subject to regimen compli-
ance, and developing a tight monitoring system,
including electronic reminders and frequent follow-up,
to be fundamental in order to enhance compliance to
treatment and testing. As suggested by a Voluntary
Counselling and Testing counsellor in Botswana:
Participant: “. the individual can be told when to come
for the next supply and when they come that’s when they
get tested.”
Interviewer: “Who would keep the card, is it the patient
or would it remain at the clinic?”
Participant: “The patient would have to keep the card so
that he can get it in any facilities so that you don’t restrict
that person to one health facility. The patient will be free
Table 4 PrEP challenges*
Policymakers Healthcare workers NGOs
Peru yRisk compensation, effectiveness,
side effects
yLow educational level,
cost-effectiveness, access
to key groups
yStigma, religious and political
barriers, access to key groups
zReligious and political barriers,
adherence, training providers
and users
zAdherence, stigma, side
effects
zSide effects, risk compensation,
adherence
xDemand (lack or excess),
access to key groups
xTraining providers and
users, risk compensation
xResistance, government support
Ukraine yCost-effectiveness, side effects,
increase in STIs
yAdherence, side effects,
training providers
yGovernment willingness,
adherence, training providers
zAdherence, access to key
groups, black market
zCost, supply, government
support
zSide effects, HIV testing, cost
xImplementation, government
support
xReligious barriers, risk
compensation
xResistance, black market
India yEfficacy, need for local trials,
risk compensation
yRisk compensation,
stigma, lack of awareness
yRisk compensation, efficacy,
need for local trials
zUsers mistrust, adherence,
supply
zAdherence, HIV testing,
users’ accessibility
zSupply, adherence, access to
key groups
xResistance, side effects xResistance, side effects xStigma, religious and political
barriers
Kenya ySupply, programme complexity,
HIV testing
yRisk compensation, cost,
adherence
yCost, training users, resistance
zResistance, limited ART coverage,
HWs’ workload
zAccess to key groups,
misconceptions and rumours,
limited ART coverage
zLimited ART coverage, supply,
adherence
xBlack market, side effects xSupply, HWs’ workload xAccess to key groups,
programme complexity
Uganda yCost, limited ART coverage,
adherence
yCost, limited ART coverage,
resistance
yCost, limited ART coverage,
user acceptability
zRisk compensation, sustainability,
government support
zAdherence, criminalisation
and stigma, risk compensation
zRisk compensation, adherence,
sustainability
xInformation and training,
HW training and workload
xSide effects, information
and training
xResistance, information and
training
Botswana yRisk compensation, HIV status
disclosure, side effects
yAdherence, cost, resistance yCost-effectiveness, risk
compensation, implementation
zAdherence, resistance, religious
barriers
zEfficacy, increase in STIs,
information and training
zResistance, criminalisation and
stigma, limited ART coverage
xCost-effectiveness, long-term
regimen
xRisk compensation, HWs
workload and levels
xAdherence, side effects
South Africa yCost-effectiveness, adherence,
cost
yAdherence, healthcare system
overload, risk compensation
yRisk compensation, adherence,
cost
zSustainability, side effects, risk
compensation
zInformation and training, cost,
limited ART coverage
zGovernment support, side effects,
information and training
xResistance, defining eligibility
criteria
xSide effects, effectiveness xEffectiveness, healthcare system
overload
*In descending order from most important and recurrent.
yHigh priority.
zMedium priority.
xLow priority.
ART, antiretroviral therapy; HWs, health workers; NGOs, non-governmental organisations; PrEP, pre-exposure prophylaxis; STI, sexually
transmitted infection.
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to go to Marina, to go to Tlokweng and get the treatment
when it’s due” (B10).
Most agreed that the PrEP route of administration
would play an important role on levels of adherence: an
injection once or every 2 months was preferred over
a daily or a before-and-after-sex pill, although a consid-
erable minority felt that offering different modalities to
match users’ needs would be a desirable option. For
example, an Indian community health worker pointed
out: “It depends on a person’s sexual interaction. If
a person has sex once a month, then he can go for
a before-and-after pill. Those who do it regularly would
want to go for the injection” (I06).
Early versus late implementation
Forty-three participants would support PrEP being
implemented early in their countries: three in Peru, five
in Ukraine, three in India, seven in Kenya, six in
Uganda, eight in Botswana and 11 in South Africa. A
Ugandan doctor working in a reproductive health clinic
illustrates this tendency: “. we needed PrEP yesterday,
I mean, what about the people who will contract HIV
Box 2 Pre-exposure prophylaxis (PrEP) challenges: important topics
Regimen
“Antiretroviral medication is quite hard to take. The patients who are involved in ARV therapy, which is a life-long therapy,
undergo special preparation .. They are taught how they should take it, how often, they are told about the side effects, what
they are allowed to do and what they aren’t allowed to do” (Uk08, doctordHIV clinic).
“ . a major concern for me is adherence . we are having challenges with people adhering to antiretrovirals . monthly
injection, that will be better” (SA02, national policymaker).
Cost and cost-effectiveness
“ . the cost of the whole service . the drug itself . we need to be able to know: is your liver functioning, is your kidney
functioning? . all those basic tests we need to do. Who’s going to bear the cost for that?” (K04, local policymaker).
“Uganda in particular doesn’t have enough ARVs, even for [HIV positive] people who urgently need them .” (Ug10, VCT
counsellor).
“I would support [PrEP] if there is evidence that it works. My benchmark would be what I invest in treatment, because one would
assume that prophylaxis has to help me spend less than what I spend on treatment” (P04, national policymaker).
Risk compensation
“. there are concerns about disinhibition with medical male circumcision, where people might believe they are now completely
immune to HIV when they’re not. I suspect the same would apply to PrEP” (SA05, local policymaker).
“The more we convince people that PrEP might protect you, the more they will relax about using condoms. Also, some are not
scared of possibly dying in 10 years” (I12, NGO representative).
Efficacy and effectiveness
“. if you have a drug of the desired efficacy, then we might begin to have a substantial reduction of new infections, assuming
the adherence is right .” (B09, doctordARV clinic).
“[PrEP] will require huge backup, especially if its efficacy is a grey area. It would require emphasizing that anybody who is using
it is not 100% protected and make sure that they use condom or get themselves tested” (I03, national policymaker).
Stigmatisation and criminalisation
“ . [PrEP implementation] will also depend on whether the next government is more conservative or more open to sexuality,
regardless of if there is scientific evidence .” (P01, national policymaker).
“Our system doesn’t take care of high risk groups at all. There is a lot of stigma; [healthcare workers] are not sensitized to deal
with these groups” (I04, local policymaker).
“ . our parliament is thinking of ways of criminalizing HIV infection . I don’t think we should go towards criminalizing HIV
infection because we are going to punish innocent people .” (Ug10, NGO representative).
Information and training
“. we have to make sure the population understands the full ramifications of the intervention. the fact that it’s only effective if
you take it constantly, the detail, not the fact that there’s a pill that can prevent HIV, that’s totally ineffective.. I would want the
message to be well nuanced, which is a play-off, because you also want it to be impactful, so it’s difficult, honest, but impactful”
(SA04, local policymaker).
“An effective program would be one that includes community awareness and education for all levels and different targeted
groups. for instance the messages to the youth may not be the same [as those] to married couples, to fishmongers, to semi-
illiterate communities . medical workers will also have to be trained” (Ug03, national policymaker).
Healthcare system capacity
“ . my main concern is around the question of logistics. How do you go about controlling the process?” (I02, national policy
maker).
“. [PrEP] will be an additional burden and most health systems can’t afford to employ more people” (Ug08, doctordHIV clinic).
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after it is found to have worked, that would have been
a missed opportunity” (Ug07). Forty-four participants,
however, would only support the introduction of PrEP
in their countries after proven safe and cost-effective
elsewhere. A Ukrainian national policymaker exem-
plifies this position: “PrEP should pass all the clinical
trials. If its effectiveness is proved, then why not?”
(Uk03). Only two participants from India, one from
Uganda and one from Botswana would not support
PrEP at all.
DISCUSSION
This is the first study to explore policymakers and
providers’ views on oral and parenteral PrEP. We found
many commonalities between participants’ opinions on
HIV prevention in general and PrEP in particular.
Interestingly, participants’ views were not significantly
influenced by their job role, yet policymakers and
healthcare workers were better at detailing the benefits
of PrEP than NGO representatives. Conversely, we
observed local differences in both the perceived benefits
and constraints of PrEP, a reflection of particular
epidemiological, socioeconomic and political contexts.
These differences should not be overlooked in the
planning of an eventual PrEP implementation.
Most participants felt that HIV prevention needed to
be enhanced to effectively tackle their epidemic. Intro-
ducing new HIV prevention modalities as part of
a combination prevention strategy was deemed necessary
to decrease HIV incidence and was also perceived as an
opportunity to expand and strengthen existing preven-
tion efforts.
Although most participants easily identified the
benefits of PrEP, were able to envisage how it would fit
into existing services and were supportive of introducing
it in their countries, they also expressed numerous
concerns. The complexity of implementing PrEP, its
cost/cost-effectiveness, partial efficacy, the ability of key
populations to access, understand and comply with it
and potential perverse effects such as increased risk
behaviours and sexually transmitted infections and the
emergence of resistance were important challenges that
deserved consideration.
Strengths and limitations of this study
Our research builds on previous qualitative work on
topical PrEP, and our results are comparable to previous
studies exploring attitudes of policymakers and imple-
menters towards microbicide gels. Hoffman et al21
compared data from the US and South Africa and found
several commonalities across job roles and settings, and
overall enthusiasm about this method, yet balanced with
concerns analogous to those found in our study. Simi-
larly, Orner et al22 found that participants’ considerable
support for microbicides was tempered by concerns
regarding effectiveness, cost, increase in risk behaviour
and challenges related to education and distribution.
Our results also resonate with the views of Piot et al,23
who urge governments, communities and scientists to
adopt HIV prevention as a national cause and ensure its
funding, to work together to build demand for HIV
prevention and to implement combination prevention
programmes against HIV, including PrEP.
This research was conducted while PrEP attributes
and effectiveness were still uncertain and only 55% of
the interviewees were aware of PrEP. In light of recent
trial results and the worldwide attention these have
received, we expect that awareness relating to this tech-
nology might be higher. However, many of the opinions
expressed here are based on previous experience and
knowledge of the local epidemic.
Although interviews were conducted in an open and
non-judgemental manner, and participants were made
aware that all data would be anonymised once it had
been analysed by our research team, given the sensitive
nature of this study, participants may at times have felt
compelled to give ‘desirable’ answers. Of similar
importance, purposively recruiting participants may
have an effect on the generalisability of our results.
Nonetheless, the many commonalities in participants’
opinions are encouraging, suggesting that it may be
possible to devise standardised PrEP programmes that
could be subsequently shaped to meet local needs.
Future research
Qualitative research undertaken using purposive
sampling enables a wide range of experiences and
opinions to emerge, but further quantitative work,
particularly among providers, is needed to determine
the true prevalence of our findings. Moreover, as clinical
trials continue to shed light on PrEP effectiveness among
different key populations, research on policymakers and
providers’ views on PrEP considering new findings, in
other countries and rural settings, is likely to provide
different accounts. Future research on the preferences
and concerns of communities’ opinion leaders and peer
educators towards PrEP would also be of considerable
value.
Impact on policy and practice
The critical question from a policy perspective is whether
countries are willing and prepared to introduce PrEP.
We have learnt from our previous study that key popu-
lations would be willing to use PrEP.16 The work
reported here demonstrates that, despite multiple
concerns, policymakers and implementers, particularly
from Sub-Saharan African countries, would also be
willing to support PrEP once it proves cost-effective.
We found that the identified barriers to PrEP were
largely comparable to the perceived HIV prevention
challenges. This suggests that current prevention short-
falls may have a bigger impact on an eventual PrEP
implementation than vice versa. Significantly reducing
HIV incidence, therefore, would require countries to
incorporate new prevention methods and to strengthen,
redirect and integrate existing prevention programmes.24
The emergence of a Combination Prevention Secretariat,
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a joint collaboration of the Bill and Melinda Gates
Foundation, PEPFAR, UNAIDS and the World Bank,
reflects the importance of this approach for donors.25
The sustainability of such integrated strategies,
however, depends on the availability of international
and local resources as much as it does on societal and
political will.
Due to the significant challenges to implementing
PrEP, including a desire to wait for PrEP programmes to
be rolled out successfully in other countries, it may be
advisable to identify early adopters to initiate feasibility
and demonstration projects with PrEP as a component
of combination prevention.
Because some key stakeholders are still unaware of
PrEP, an important aspect of initial work will be to
provide information about PrEP, including its rationale,
benefits and drawbacks. Comprehensive training
programmes for providers and users, and targeted
communication strategies, which encompass wider issues
related to stigma and the specific needs of those most at
risk of HIV infection, ought to be developed and tested
before introducing PrEP.
The results of this study have implications for PrEP
feasibility and demonstration projects. Our data indicate
that PrEP should be offered to key populations in the first
instance, although reaching some of these groups26 27
and prioritising specific populations in settings with
generalised epidemics, is likely to be challenging. PrEP
should be coordinated by the Ministries of Health and
involve relevant NGOs and community representatives.
Effective and affordable information channels should
include existing healthcare services, peer educators,
community leaders, social networks and targeted mass
media advertising. PrEP should mainly be offered in
public and NGO-based healthcare services as part of
a combination prevention package and be decoupled
from specialised ART services to avoid stigmatisation. An
integrated service that would allow mobile populations to
access PrEP in different areas should be considered. The
ongoing decentralisation of HIV services towards primary
care, promoted by funders, is a step in the right direc-
tion.28 PrEP should be affordable and its price could be
segmented. All available PrEP routes of administration
should be offered, although parenteral PrEP, when and if
becomes available, would be easier to adhere to. Coun-
selling and frequent monitoring, as well as introducing
innovative measures to increase regimen adherence, such
as contractual agreements between providers and users,
and the use of mobile technology, may limit the emer-
gence of resistance to antiretrovirals and increase PrEP
effectiveness.
More profound societal and legislative changes, aimed
at tackling widespread stigma, may be necessary for new
HIV prevention approaches in general, and particularly
those directed at stigmatised populations, to be fully
successful. The enthusiasm and debate surrounding
scientific breakthroughs like PrEP have the potential to
become a catalyst for change.
Author affiliations
1Centre for Patient Safety and Service Quality, Imperial College London,
London, UK
2Imperial College Business School, London, UK
3Amsterdam Institute for Global Health and Development, Amsterdam,
Netherlands
4Ipsos MORI Social Research Institute, London, UK
5Georgetown O’Neill Institute for National and Global Health Law, Washington,
DC, USA
6George W. Bush Institute, Dallas, Texas, USA
7London School of Hygiene and Tropical Medicine, London, UK
Acknowledgements We are very grateful to all the policymakers, healthcare
workers and NGO representatives who participated in this study and the Bill
& Melinda Gates Foundation, in particular Blair Hanewall and Stephen
Becker, for funding our research. We would also like to thank Kate Duxbury
and the Ipsos MORI team, as well as the local research teamsdIpsos Apoyo
(Peru), Ukrainian Institute of Social Research, Kadence International (India),
Research Solutions (Kenya and Uganda), Sketches (Botswana) and Ipsos
Markinor (South Africa)dfor their valuable advice and management support
throughout this study. The authors would finally like to thank Geoffrey
Garnett (Imperial College) for his guidance at the beginning of this study
Anam Parand, Anna Pinto and Timothy Hallett (Imperial College London) for
their useful comments during the preparation of this manuscript.
Contributors AW, ABE, GBG, EG, MRD and PP agree with the manuscript’s
results and conclusions. ABE and AW designed the measures/the study with
the support of EG and PP. AW, GBG and ABE reviewed the available data and
literature and performed the analyses. All authors contributed to the
interpretation of results and write-up. MRD was principal investigator for the
grant. PP and ABE were investigators for the grant at Imperial College London.
Funding The sponsor of the study, the Bill & Melinda Gates Foundation, had no
role in study design, data collection, data analysis or write-up of the paper.
Competing interests The authors have declared that no competing interests
exist.
Ethics approval This study was approved by the Ethics Committee of
Imperial College London, the Universidad Peruana Cayetano Heredia in Peru,
the Sociological Association of Ukraine (SAU), the Independent Ethics
Committee Consultants (IEC) in India, the Institutional Review Board of the
Kenya Medical Research Institute (KEMRI), the Director General Health
Services of the Ministry of Health in Uganda, the Health Research and
Development Division of the Ministry of Health in Botswana and the Human
Research Ethics Committee (Medical) of the University of Witwatersrand in
South Africa.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement There are no additional data available.
REFERENCES
1. UNAIDS, WHO, UNICEF. GLOBAL HIV/AIDS
RESPONSEdEpidemic Update and Health Sector Progress
Towards Universal Access. Geneva, Switzerland: UNAIDS, WHO,
UNICEF, 2011.
2. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al; CAPRISA 004
Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral
microbicide, for the prevention of HIV infection in women. Science
2010;329:1168e74.
3. Grant RM, Lama JR, Anderson PL, et al; iPrEx Study Team.
Preexposure chemoprophylaxis for HIV prevention in men who have
sex with men. N Engl J Med 2010;363:2587e99.
4. Cohen MS, Chen YQ, McCauley M, et al; HPTN 052 Study Team.
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J
Med 2011;365:493e505.
5. Thigpen M, Kebaabetswe P, Smith D, et al. Daily Oral Antiretroviral
Use for the Prevention of HIV Infection in Heterosexually Active
Young Adults in Botswana: Results From the TDF2 Study. 6th IAS
Conference. Rome, Italy. WELBC01 oral abstract. http://pag.ias2011.
org/abstracts.aspx?aid¼4631 (accessed 8 Dec 2011).
6. Baeton J, Celum C. Antiretroviral Pre-exposure Prophylaxis for HIV-1
Prevention Among Heterosexual African Men and Women: The
Partners PrEP Study. 6th IAS Conference. Rome, Italy. Abstract
MOAX0106. http://pag.ias2011.org/flash.aspx?pid¼886 (accessed 8
Dec 2011).
10 Wheelock A, Eisingerich AB, Gomez GB, et al. BMJ Open 2012;2:e001234. doi:10.1136/bmjopen-2012-001234
Views of policymakers, healthcare workers and NGOs on PrEP
7. Van Damme L, Corneli A, Ahmed K, et al. The FEM-PrEP trial of
emtricitabine/tenofovir disoproxil fumarate (Truvada)
among African women. 19th Conference on Retroviruses
and Opportunistic Infections; 5e8 March 2012, Seattle. Abstract
32LB.
8. MTN. Press Release: Microbicide Trials Network Statement on
Decision to Discontinue Use of Oral Tenofovir Tablets in Voice,
a Major HIV Prevention Study in Women. Microbicide Trials Network
(MTN), Pittsburgh, 2011.
9. Kashuba AD, Patterson KB, Dumond JB, et al. Pre-exposure
prophylaxis for HIV prevention: how to predict success. Lancet.
Published Online First: 6 December 2011. doi:10.1016/S0140-6736
(11)61852-7
10. Underhill K, Operario D, Mimiaga MJ, et al. Implementation Science
of pre-exposure prophylaxis: preparing for public use. Curr HIV/AIDS
Rep 2010;7:210e19.
11. Kim SC, Becker S, Dieffenbach C, et al. Planning for pre-exposure
prophylaxis to prevent HIV transmission: challenges and
opportunities. J Int AIDS Soc 2010;13:24.
12. Buchbinder S, Liu A. Pre-exposure prophylaxis and the promise of
combination prevention approaches. AIDS Behav 2011;15(Suppl 1):
S72e9.
13. Coates TJ, Richter L, Caceres C. Behavioural strategies to reduce
HIV transmission: how to make them work better. Lancet
2008;372:669e84.
14. Myers GM, Mayer KH. Oral preexposure Anti-HIV prophylaxis for
high-risk U.S. Populations: current considerations in light of new
findings. AIDS Patient Care STDS 2011;25:63e71.
15. Bertozzi SM, Laga M, Bautista-Arredondo S, et al. Making HIV
prevention programmes work. Lancet 2008;372:831e44.
16. Eisingerich AB, Wheelock A, Gomez GB, et al. Attitudes and
acceptance of oral and parenteral HIV preexposure prophylaxis
among potential user groups: a Multinational study. PLoS ONE 2012;7:
e28238.
17. Greenhalgh T, Taylor R. How to read a paper: papers that go beyond
numbers (qualitative research). BMJ 1997;315:740e3.
18. Pope C, Ziebland S, Mays N. Qualitative research in health care. BMJ
2000;320:114e16.
19. Silverman D. Interpreting Qualitative Data: Methods for Analyzing
Talk, Text, and Interaction. 3rd edn. London: Sage, 2001.
20. Flick U. An Introduction to Qualitative Research. 4th edn. London:
Sage, 2009.
21. Hoffman S, Cooper D, Ramjee G, et al. Microbicide acceptability:
insights for future directions from providers and policy makers. AIDS
Educ Prev 2008;20:188e202.
22. Orner P, Harries J, Cooper D, et al. Challenges to microbicide
introduction in South Africa. Soc Sci Med 2006;63:968e78.
23. Piot P, Bartos M, Larson H, et al. Coming to terms with
complexity: a call to action for HIV prevention. Lancet
2008;372:845e59.
24. Merson MH, O’Malley J, Serwadda D, et al. The history and challenge
of HIV prevention. Lancet 2008;372:475e88.
25. Padian NS, McCoy SI, Manian S, et al. Evaluation of large-scale
combination HIV prevention programs: essential issues. J Acquir
Immune Defic Syndr 2011;58:e23e8.
26. Rankin WW, Brennan S, Schell E, et al. The stigma of being HIV-
positive in Africa. PLoS Med 2005;2:e247.
27. Ekstrand M, Bharat S, Ramakrishna J, et al. Blame, symbolic stigma
and HIV Misconceptions are associated with support for Coercive
measures in urban India. AIDS Behav 2012;16:1e11.
28. Schwartla¨nder B, Stover J, Hallett T, et al; Investment
Framework Study Group. Towards an improved investment
approach for an effective response to HIV/AIDS. Lancet
2011;377:2031e41.
PAGE fraction trail=10.5
Wheelock A, Eisingerich AB, Gomez GB, et al. BMJ Open 2012;2:e001234. doi:10.1136/bmjopen-2012-001234 11
Views of policymakers, healthcare workers and NGOs on PrEP
